Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
Holding LIVN?
Track your performance easily
LIVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.15 - $64.48
Previous Close$46.56
Volume332.90K
Average Volume (3M)493.01K
Market Cap
$2.53B
Enterprise Value$2.85B
Total Cash (Recent Filing)$346.37M
Total Debt (Recent Filing)$670.32M
Price to Earnings (P/E)109.2
Beta1.24
Next Earnings
Feb 19, 2025EPS Estimate
$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding54,300,835
10 Day Avg. Volume511,735
30 Day Avg. Volume493,008
Standard Deviation0.11
R-Squared0.24
Alpha-0.01
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.93
Price to Sales (P/S)2.04
Price to Cash Flow (P/CF)12.40
P/FCF Ratio19.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.30
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda59.13
Forecast
1Y Price Target
$70.00Price Target Upside53.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
LivaNova News
PremiumStock Analysis & Ideas
Goldman Sachs Says Improving Growth Could Propel These 2 Stocks Higher
PremiumCompany Announcements
LivaNova PLC Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessLIVN announced that its OSPREY clinical trial of its aura600 hypoglossal nerve stimulation device for obstructive sleep apnea met its primary efficacy and safety endpoints without any serious adverse events.
Financial Performance And GrowthLIVN posted a sizable $+18mn/$0.18 beat for 3Q driven by strength across the CP segment and share gains in Oxygenators, as the competitive landscape remains favorable.
Product Launch And Market PotentialLIVN's aura6000 is likely to become INSP's first fully implantable competitor, targeting the large OSA market with an estimated 54 million people in the US alone.
Bears Say
Financial PerformanceLIVN shares have struggled to find periods of outperformance, as strategic shifts in the business and pipeline setbacks have resulted in flattish revenue from 2015-2023.
Market CompetitionNyxoah's Genio, which is not fully implantable, is likely to beat LIVN to the market with an FDA approval in 1H25.
Revenue GrowthThe epilepsy device replacements may slow resulting in slightly slower overall revenue growth.
---
Ownership Overview
0.29% Insiders
27.36% Mutual Funds
30.15% Other Institutional Investors
23.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $43.15 and its highest was $64.47 in the past 12 months.
What is LivaNova PLC’s market cap?
Currently, no data Available
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Feb 19, 2025 which is in 50 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Oct 30, 2024. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.717 by $0.183.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is $0.8.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,300,835 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.9 in its last earnings report, beating expectations of $0.717. Following the earnings report the stock price went down -3.077%.
Which hedge fund is a major shareholder of LivaNova PLC?
Among the largest hedge funds holding LivaNova PLC’s share is PRIMECAP Management Co. It holds LivaNova PLC’s shares valued at 296M.
---
LivaNova Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.00 (53.17% Upside)
$70.00 (53.17% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 803.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 16.3%
Last 30 Days ▼ 16.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.80%
12-Months-Change
Fundamentals
Return on Equity
1.86%
Trailing 12-Months
Asset Growth
8.27%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company's shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
---
LIVN Company Deck
---
LIVN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth, successful product launches, and increased future guidance. However, there were challenges noted in specific segments, such as epilepsy revenue declines in Europe and higher R&D expenses. The tax rate increase also poses a potential headwind.Read More>---
LIVN Stock 12 Month Forecast
Average Price Target
$70.00
▲(53.17% Upside)
Technical Analysis
Best Analysts Covering LIVN
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-9.75%
assigned a buy rating 2 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -9.75% per trade.
---